312 related articles for article (PubMed ID: 34885245)
21. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Lin CH; Tariq MJ; Ullah F; Sannareddy A; Khalid F; Abbas H; Bader A; Samaras C; Valent J; Khouri J; Anwer F; Raza S; Dima D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892379
[TBL] [Abstract][Full Text] [Related]
22. Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies.
Papadimitriou M; Ahn S; Diamond B; Lee H; McIntyre J; Truger M; Durante M; Ziccheddu B; Landgren O; Rasche L; Bahlis NJ; Neri P; Maura F
bioRxiv; 2024 May; ():. PubMed ID: 38826396
[TBL] [Abstract][Full Text] [Related]
23. Structure and function of therapeutic antibodies approved by the US FDA in 2023.
Strohl WR
Antib Ther; 2024 Apr; 7(2):132-156. PubMed ID: 38617189
[TBL] [Abstract][Full Text] [Related]
24. Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020.
Bobin A; Liuu E; Moya N; Gruchet C; Sabirou F; Lévy A; Gardeney H; Nsiala L; Cailly L; Guidez S; Tomowiak C; Systchenko T; Javaugue V; Durand G; Leleu X; Puyade M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050025
[TBL] [Abstract][Full Text] [Related]
25. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
26. Talquetamab: First Approval.
Keam SJ
Drugs; 2023 Oct; 83(15):1439-1445. PubMed ID: 37792138
[TBL] [Abstract][Full Text] [Related]
27. Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Rais T; Khan A; Riaz R
Rare Tumors; 2023; 15():20363613231207483. PubMed ID: 37840703
[TBL] [Abstract][Full Text] [Related]
28. T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687588
[TBL] [Abstract][Full Text] [Related]
29. The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma.
Schinke C
Chin Clin Oncol; 2024 Mar; ():. PubMed ID: 38462921
[No Abstract] [Full Text] [Related]
30. Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.
Yin X; Liu Y; Sun J; Tong H; Meng H; You L
Ther Adv Chronic Dis; 2023; 14():20406223231213251. PubMed ID: 38028949
[TBL] [Abstract][Full Text] [Related]
31. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.
Xu L; Wen C; Xia J; Zhang H; Liang Y; Xu X
Cell Death Discov; 2024 Jan; 10(1):55. PubMed ID: 38280847
[TBL] [Abstract][Full Text] [Related]
32. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
33. The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.
Yan P; Lin X; Wu L; Xu L; Li F; Liu J; Xu F
Nat Commun; 2024 Jun; 15(1):5255. PubMed ID: 38898050
[TBL] [Abstract][Full Text] [Related]
34. Antibody-based therapies in multiple myeloma.
Tai YT; Anderson KC
Bone Marrow Res; 2011; 2011():924058. PubMed ID: 22046572
[TBL] [Abstract][Full Text] [Related]
35. Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Derrien J; Gastineau S; Frigout A; Giordano N; Cherkaoui M; Gaborit V; Boinon R; Douillard E; Devic M; Magrangeas F; Moreau P; Minvielle S; Touzeau C; Letouzé E
Nat Cancer; 2023 Nov; 4(11):1610. PubMed ID: 37684528
[No Abstract] [Full Text] [Related]
36. FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma.
Mullard A
Nat Rev Drug Discov; 2023 Oct; 22(10):775. PubMed ID: 37673980
[No Abstract] [Full Text] [Related]
37. Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Mar; 14(1):40. PubMed ID: 38448422
[No Abstract] [Full Text] [Related]
38. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
Cho SF; Yeh TJ; Anderson KC; Tai YT
Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
[TBL] [Abstract][Full Text] [Related]
39. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
